Field |
Value |
Language |
dc.contributor.author |
Bisht, A |
|
dc.contributor.author |
Hemrajani, C |
|
dc.contributor.author |
Rathore, C |
|
dc.contributor.author |
Dhiman, T |
|
dc.contributor.author |
Rolta, R |
|
dc.contributor.author |
Upadhyay, N |
|
dc.contributor.author |
Nidhi, P |
|
dc.contributor.author |
Gupta, G |
|
dc.contributor.author |
Dua, K
https://orcid.org/0000-0002-7507-1159
|
|
dc.contributor.author |
Chellappan, DK |
|
dc.contributor.author |
Dev, K |
|
dc.contributor.author |
Sourirajan, A |
|
dc.contributor.author |
Chakraborty, A |
|
dc.contributor.author |
Aljabali, AAA |
|
dc.contributor.author |
Bakshi, HA |
|
dc.contributor.author |
Negi, P |
|
dc.contributor.author |
Tambuwala, MM |
|
dc.date.accessioned |
2021-11-16T05:40:45Z |
|
dc.date.available |
2021-11-16T05:40:45Z |
|
dc.identifier.citation |
Drug Delivery and Translational Research |
|
dc.identifier.issn |
2190-393X |
|
dc.identifier.issn |
2190-3948 |
|
dc.identifier.uri |
http://hdl.handle.net/10453/151632
|
|
dc.description.abstract |
<jats:title>Abstract</jats:title><jats:p>Azelaic acid (AzA) is a USFDA bioactive prescribed against <jats:italic>acne vulgaris</jats:italic>. It possesses delivery challenges like poor aqueous solubility, low skin-penetrability, and dose-dependent side effects, which could be overcome by its synergistic combination with tea tree oil (TTO) as a microemulsion (ME)-based hydrogel composite. AzA-TTO ME was prepared to employ pseudo-ternary phase diagram construction. The best AzA-TTO ME was of uniform size (polydispersity index < 0.7), nano-range (~357.4 ± 2% nm), transmittance (> 90%), and negative zeta potential (−1.42 ± 0.25% mV) values. ME hydrogel composite with optimum rheological and textural attributes showed better permeation, retention, and skin-compliant characteristics, vis-a-vis marketed formulation (Aziderm™) when evaluated in Wistar rat skin. In vitro antibacterial efficacy in bacterial strains, i.e., <jats:italic>Staphylococcus aureus</jats:italic>, <jats:italic>Propionibacterium acne</jats:italic>, and <jats:italic>Staphylococcus epidermidis</jats:italic>, was evaluated employing agar well plate diffusion and broth dilution assay. ME hydrogel has shown an increase in zone of inhibition by two folds and a decrease in minimum inhibitory concentration (MIC) by eightfold against <jats:italic>P. acnes</jats:italic> vis-a-vis AzA. Finally, ME hydrogel composite exhibited a better reduction in the papule density (93.75 ± 1.64%) in comparison to Aziderm™ 72.69 ± 4.67%) on acne as developed in rats by inducing testosterone. Thus, the developed AzA-TTO ME hydrogel composite promises an efficacious and comparatively safer drug delivery system for the topical therapy of <jats:italic>acne vulgaris</jats:italic>.</jats:p>
<jats:p><jats:bold>Graphical abstract</jats:bold></jats:p> |
|
dc.language |
en |
|
dc.publisher |
Springer Science and Business Media LLC |
|
dc.relation.ispartof |
Drug Delivery and Translational Research |
|
dc.relation.isbasedon |
10.1007/s13346-021-01092-4 |
|
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject |
1115 Pharmacology and Pharmaceutical Sciences |
|
dc.title |
Hydrogel composite containing azelaic acid and tea tree essential oil as a therapeutic strategy for Propionibacterium and testosterone-induced acne |
|
dc.type |
Journal Article |
|
utslib.for |
1115 Pharmacology and Pharmaceutical Sciences |
|
pubs.organisational-group |
/University of Technology Sydney |
|
pubs.organisational-group |
/University of Technology Sydney/Faculty of Health |
|
pubs.organisational-group |
/University of Technology Sydney/Faculty of Health/Graduate School of Health |
|
pubs.organisational-group |
/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy |
|
utslib.copyright.status |
closed_access |
* |
dc.date.updated |
2021-11-16T05:40:43Z |
|
pubs.publication-status |
Published online |
|